China Biotech Hotter Than AI - Here Are 3 ETFs For Momentum Play

China’s biotech sector is on fire.

Pfizer signed a multi-billion dollar deal (up to US$6 billion total) with 3SBio for rights to a breakthrough PD-1/VEGF cancer therapy. Just weeks later, Bristol Myers Squibb and BioNTech inked an $11 billion partnership for another Chinese-developed antibody treatment. These headline-grabbing deals – focused on cutting-edge immuno-oncology drugs – have sparked a surge in investor interest.

This has triggered a broad rally in Hong Kong–listed biotech stocks. Some have gained over 200% year-to-date.

But for most investors, picking individual biotech winners is tough – the sector is volatile and technically complex. Fortunately, exchange-traded funds (ETFs) offer a simpler way to ride the momentum without needing to bet on a single name.

Below are three biotech ETFs listed in Hong Kong that give diversified exposure to this biotech boom.